Ardelyx, Inc.

NasdaqGM:ARDX

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Drugstores & Retail Pharmacies

🌿 Fertilizers

💊 Pharmaceuticals

Location

United States

Market Cap

USD 863.71 M

Share Price

USD 3.61

Avg Daily Volume

5,353,574

Change (1 day)

1.69%

Change (1 year)

-39.33%

Change (YTD)

-28.80%

Ardelyx, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending March 31, 2025: -3.45

Ardelyx, Inc. Interest Coverage Ratio is -3.45 for the Trailing 12 Months (TTM) ending March 31, 2025, a -30.34% change year over year. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.

Ardelyx, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending March 31, 2024 was -4.96, a -47.63% change year over year.
Ardelyx, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was -9.47, a -73.50% change year over year.
Ardelyx, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was -35.74, a 72.47% change year over year.
Ardelyx, Inc. Interest Coverage Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was -20.72, a 36.63% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Interest Coverage Ratio	Return on Capital Employed (ROCE)	Return on Equity (ROE)	Return on Assets (ROA)

NasdaqGM: ARDX

Ardelyx, Inc.

CEO	Mr. Michael G. Raab
IPO Date	June 19, 2014
Location	United States
Headquarters	400 Fifth Avenue
Employees	395
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Drugstores & Retail Pharmacies 🌿 Fertilizers 💊 Pharmaceuticals

Description

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.